Jim Simons Lantern Pharma Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 84,000 shares of LTRN stock, worth $273,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,000

Previous 81,800 2.69%

Holding current value

$273,000

Previous $382,000 19.37%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.42 - $4.83 $7,524 - $10,626	2,200 Added 2.69%	84,000 $308,000
Q2 2024 Aug 09, 2024	BUY	$3.91 - $9.51 $62,951 - $153,111	16,100 Added 24.51%	81,800 $382,000
Q1 2024 May 13, 2024	BUY	$3.73 - $10.65 $81,687 - $233,235	21,900 Added 50.0%	65,700 $578,000
Q4 2023 Feb 13, 2024	BUY	$2.48 - $4.39 $14,136 - $25,022	5,700 Added 14.96%	43,800 $187,000
Q3 2023 Nov 14, 2023	SELL	$3.41 - $5.51 $23,188 - $37,468	-6,800 Reduced 15.14%	38,100 $130,000
Q2 2023 Aug 11, 2023	BUY	$4.56 - $6.02 $92,567 - $122,205	20,300 Added 82.52%	44,900 $253,000
Q1 2023 May 12, 2023	BUY	$4.3 - $6.2 $15,050 - $21,700	3,500 Added 16.59%	24,600 $119,000
Q4 2022 Feb 13, 2023	SELL	$4.19 - $6.04 $838 - $1,208	-200 Reduced 0.94%	21,100 $127,000
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $3,672 - $5,200	-800 Reduced 3.62%	21,300 $102,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.45 $54,948 - $84,930	11,400 Added 106.54%	22,100 $126,000
Q1 2022 May 13, 2022	BUY	$5.6 - $8.22 $59,919 - $87,954	10,700 New	10,700 $77,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.31M

Call Options Held

39.8K

Put Options Held

6.1K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $35.2M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account